中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

452 records (took 0.023 seconds)

    Prostate cancer prognostic compositions and kits
    101.
    发明授权
    Prostate cancer prognostic compositions and kits 有权
    前列腺癌预后组成和试剂盒

    公开(公告)号：US09096907B2

    公开(公告)日：2015-08-04

    申请号：US13914303

    申请日：2013-06-10

    Applicant: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen

    Inventor： Daphne Hessels ,  Gerald Verhaegh ,  Jack A. Schalken ,  J. Alfred Witjes

    IPC: C12Q1/68

    CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57434 ,  G01N2333/96455

    Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

    Abstract translation: 本文描述了前列腺癌预后的方法，组合物和试剂盒。 该方法包括确定尿样中PCA3和前列腺特异性标志物表达的比例，并将PCA3 /前列腺特异性标志物比值与受试者中前列腺癌的侵袭性和死亡风险相关联。 在患者样品中预测前列腺癌的方法包括评估前列腺癌特异性PCA3 mRNA的量和样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。

    METHOD FOR THE PREPARATION OF HIGH MOLECULAR WEIGHT OLIGO(ALKYLENE GLYCOL) FUNCTIONALIZED POLYISOCYANOPEPTIDES
    102.
    发明申请
    METHOD FOR THE PREPARATION OF HIGH MOLECULAR WEIGHT OLIGO(ALKYLENE GLYCOL) FUNCTIONALIZED POLYISOCYANOPEPTIDES 审中-公开
    制备高分子量OLIGO（亚苄基甘油）官能化聚异氰尿酸酯的方法

    公开(公告)号：US20150105516A1

    公开(公告)日：2015-04-16

    申请号：US14577038

    申请日：2014-12-19

    Applicant: Stichting Katholieke Universiteit Meer in Het Bijzonder Radboud University Nijmegen

    Inventor： Alan Edward Rowan ,  Roeland Johannes Maria Nolte ,  Jeroen Johannes Lambertus Maria Cornelissen ,  Heather Joy Kitto ,  Erik Schwartz ,  Matthieu Koepf

    IPC: C08G69/40 ,  C09D177/04 ,  C08L77/04

    CPC classification number: C08G69/40 ,  C08G65/33348 ,  C08L77/04 ,  C08L2201/54 ,  C09D177/04

    Abstract: The present invention relates to a process for the preparation of oligo(alkylene glycol)-functionalized polyisocyanopeptides comprising the steps of functionalizing an isocyanopeptide with oligo-(alkylene glycol) side chains and subsequently polymerizing the oligo-alkylene glycol-functionalized isocyanopeptides. Several isocyanopeptides may be functionalized with various linear or non-linear oligo-(alkylene glycol) side chains having variable chain length. The alkylene glycol may be selected from the group consisting of ethylene-, propylene-, butylene- or pentylene glycol. Preferably, the isocyanopeptides are functionalized with at least three ethylene glycol side chains. The peptides may comprise L-amino acids, D-amino acids or D, L-amino acids. The obtained oligoalkylene-functionalized polyisocyanopeptides are a new class of materials with unique thermo-responsive properties.

    Abstract translation: 本发明涉及制备低聚（亚烷基二醇）官能化多异氰酸肽的方法，其包括以低聚（亚烷基二醇）侧链官能化异氰尿酸并随后聚合低聚 - 亚烷基二醇官能化的异氰尿苷的步骤。 可以用具有可变链长度的各种线性或非线性寡（亚烷基二醇）侧链来官能化几种异氰酸酯。 亚烷基二醇可以选自乙烯 - ，丙烯 - ，丁烯 - 或戊二醇。 优选地，异氰酸肽用至少三个乙二醇侧链进行官能化。 肽可以包含L-氨基酸，D-氨基酸或D，L-氨基酸。 获得的低聚亚烷基官能化多异氰酸肽是具有独特热响应特性的新一类材料。

    Methods for the treatment or prevention of systemic sclerosis
    103.
    发明授权
    Methods for the treatment or prevention of systemic sclerosis 有权
    治疗或预防系统性硬化症的方法

    公开(公告)号：US08920802B2

    公开(公告)日：2014-12-30

    申请号：US13928557

    申请日：2013-06-27

    Applicant: Stichting Katholieke Universiteit

    Inventor： Timothy Ruben Dirk Jan Radstake

    IPC: A61K39/00 ,  A61K39/395 ,  A61K38/17

    CPC classification number: A61M1/3618 ,  A61K38/17 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2851 ,  C07K2317/76

    Abstract: The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.

    Abstract translation: 本发明涉及分子免疫学领域，特别是在预防或治疗自身免疫性疾病领域，特别是系统性硬化症或硬皮病领域。 本发明是基于SSC患者血浆CXCL4水平升高的观察。 这被发现有助于SSc的发病机制，特别是纤维化。 当CXCL4在体外实验中被中和时，可以中和纤维化作用。 这导致我们得出结论，通过降低CXCL4的血浆水平可以治愈SSc。 因此，本发明涉及用于治疗或预防硬皮病患者纤维化的方法，其中CXCL4的血浆水平降低。

    METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS
    104.
    发明申请
    METHODS FOR THE TREATMENT OR PREVENTION OF SYSTEMIC SCLEROSIS 有权
    治疗或预防系统性溃疡的方法

    公开(公告)号：US20140370033A1

    公开(公告)日：2014-12-18

    申请号：US14471968

    申请日：2014-08-28

    Applicant: Stichting Katholieke Universiteit

    Inventor： Timothy Ruben Dirk Jan Radstake

    IPC: C07K16/24 ,  C07K16/28 ,  C07K16/18

    CPC classification number: A61M1/3618 ,  A61K38/17 ,  A61K39/39541 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2851 ,  C07K2317/76

    Abstract: The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that SSC patients have an elevated plasma level of CXCL4. This was found to contribute to the pathogenesis of SSc, in particular, fibrosis. When CXCL4 was neutralized in in vitro experiments, the fibrotic effects could be neutralized. This led us to conclude that SSc may be cured by reducing the plasma level of CXCL4. The invention, therefore, relates to a method for treatment or prevention of fibrosis in patients with scleroderma, wherein the plasma level of CXCL4 is reduced.

    Abstract translation: 本发明涉及分子免疫学领域，特别是在预防或治疗自身免疫性疾病领域，特别是系统性硬化症或硬皮病领域。 本发明是基于SSC患者血浆CXCL4水平升高的观察。 这被发现有助于SSc的发病机制，特别是纤维化。 当CXCL4在体外实验中被中和时，可以中和纤维化作用。 这导致我们得出结论，通过降低CXCL4的血浆水平可以治愈SSc。 因此，本发明涉及用于治疗或预防硬皮病患者纤维化的方法，其中CXCL4的血浆水平降低。

    BREATH SAMPLER
    107.
    发明申请
    BREATH SAMPLER 有权

    公开(公告)号：US20220031189A1

    公开(公告)日：2022-02-03

    申请号：US17275701

    申请日：2019-09-13

    Applicant: STICHTING KATHOLIEKE UNIVERSITEIT

    Inventor： Marinus Isaäk de Jonge ,  Cornelis Hubertus van den Kieboom

    IPC: A61B5/08 ,  A61B5/097 ,  A61B5/091

    Abstract: A breath sampler for collecting a breath sample from a patient is disclosed. The breath sampler has a non-rebreather part including a sample inlet, a one-way outlet valve downstream of the sample inlet, and an air inlet. The one-way outlet valve and the sample inlet define a first portion of an internal breath flow pathway therebetween. The air inlet is arranged to be closed by a one-way inlet valve arranged to allow air to enter the non-rebreather part. The breath sampler also has a sample delivery part in fluid communication with the non-rebreather part at an upstream end via the one-way outlet valve. The sample delivery part defines a second portion of the internal breath flow pathway, and has an air diverter, a sample outlet, a return inlet and a sample collection chamber connector. The air diverter is arranged to divide the sample delivery part into an upstream portion upstream of the air diverter and a downstream portion downstream of the air diverter and is configured to divert the breath sample into a sample collection chamber including a liquid capture interface. The sample collection chamber is coupled to the sample collection chamber connector and includes a liquid capture interface.

    HEART SUPPORT DEVICE WITH DIRECTIONAL FLOW ASSIST
    108.
    发明申请
    HEART SUPPORT DEVICE WITH DIRECTIONAL FLOW ASSIST 有权

    公开(公告)号：US20210244935A1

    公开(公告)日：2021-08-12

    申请号：US17263554

    申请日：2019-07-26

    Applicant: Stichting Katholieke Universiteit

    Inventor： Daniël Immanuel Michaël van Dort

    IPC: A61M60/17 ,  A61M60/148 ,  A61M60/268 ,  A61M60/497 ,  A61M60/812

    Abstract: A heart support device for circulatory assistance is disclosed. The device comprises a chamber body (10) defining a chamber having an internal volume configured to be filled with blood. The chamber body (10) has a first opening (12) and the chamber is dimensioned such that the first opening (12) and the chamber are fully disposed within a chamber of the human heart. A dynamic volume body (14) is provided and configured to be inflated or deflated to alternately increase or decrease the interior volume of the chamber. A catheter (16) comprising at least one lumen in fluid communication with the dynamic volume body is configured to deliver fluid to the dynamic volume body to inflate the dynamic volume body. A directional flow structure is configured to direct a flow of blood out of the chamber in a direction substantially aligned with a direction in which the catheter (16) extends.

Patent Agency Ranking